| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Cefprozil targets penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. By binding to these proteins, it inhibits bacterial cell wall synthesis, leading to cell lysis and death.
|
|---|---|
| ln Vitro |
In vitro, Cefprozil hydrate exhibits broad-spectrum antibacterial activity against a range of Gram-positive and Gram-negative bacteria. It is resistant to hydrolysis by some beta-lactamases. Its activity is measured by minimum inhibitory concentration (MIC) determinations against various bacterial strains.
|
| ln Vivo |
In vivo, Cefprozil hydrate has demonstrated antibacterial activity in animal models of infection. It is effective in treating infections when administered orally or via injection. Its efficacy in human patients has been established for respiratory, skin, and ear infections.
|
| Enzyme Assay |
In vitro antibacterial susceptibility testing for Cefprozil hydrate is performed using standardized methods such as broth microdilution or disk diffusion (Kirby-Bauer). The compound is tested against a panel of bacterial isolates, including both standard reference strains (e.g., ATCC) and clinical isolates. The minimum inhibitory concentration (MIC) is determined as the lowest concentration that inhibits visible bacterial growth after overnight incubation.
|
| Cell Assay |
In vitro cellular assays are not typically used for antibiotics like Cefprozil, as their primary activity is against bacteria, not mammalian cells. However, the compound's mechanism of action can be studied in bacterial cell cultures by measuring its effect on cell wall synthesis, for example, by assessing the incorporation of radiolabeled precursors into the peptidoglycan layer.
|
| Animal Protocol |
In vivo animal studies for Cefprozil hydrate are conducted in rodent models of infection, such as murine septicemia or pneumonia models. Animals are infected with a pathogenic bacterial strain (e.g., Streptococcus pneumoniae, Staphylococcus aureus), and the compound is administered orally or parenterally. The protective effect is measured by survival rate, reduction in bacterial load in target organs, or resolution of infection symptoms.
|
| ADME/Pharmacokinetics |
Cefprozil hydrate is well absorbed orally. It is partially metabolized and excreted renally. The drug's PK profile allows for twice-daily dosing in clinical settings. Its oral bioavailability and half-life have been characterized in humans.
|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation Limited information currently available indicates that the concentration of cefprozil in breast milk is low and is not expected to have adverse effects on breastfed infants. There are reports that cephalosporins occasionally disrupt the infant's gut microbiota, leading to diarrhea or thrush, but these effects have not been fully assessed. Cefprozil is safe for use by breastfeeding women. ◉ Effects on Breastfed Infants No published information found as of the revision date. ◉ Effects on Lactation and Breast Milk No published information found as of the revision date. Cefprozil hydrate has a well-established safety profile. Common adverse effects include diarrhea, nausea, rash, and hypersensitivity reactions. As with other cephalosporins, there is a risk of cross-reactivity in patients with penicillin allergy. It is generally well-tolerated. |
| References |
: Jerath N, Shetty G. Redefining the management of pediatric tonsillopharyngitis with cefprozil. Indian J Pediatr. 2007 Dec;74(12):1105-8. Review. PubMed PMID: 18174646.
|
| Additional Infomation |
Cefprozil is a semi-synthetic cephalosporin β-lactam antibiotic with bactericidal activity. Cefprozil's action depends on its binding to penicillin-binding proteins (PBPs) located on the bacterial cell membrane. This binding inhibits transpeptidase activity, thereby preventing the cross-linking of the pentagaryl bridge to the fourth amino acid residue of the pentapeptide and interrupting subsequent peptidoglycan chain synthesis. Therefore, cefprozil inhibits the synthesis of bacterial septa and cell walls. Cefprozil (E) is the E-isomer of the semi-synthetic cephalosporin β-lactam antibiotic with bactericidal activity. Cefprozil's action depends on its binding to penicillin-binding proteins (PBPs) located on the bacterial cell membrane. After binding, transpeptidase activity is inhibited, thereby preventing the cross-linking of the pentagaryl bridge to the fourth amino acid residue of the pentapeptide, and thus blocking peptidoglycan chain synthesis. Therefore, cefprozil inhibits the synthesis of bacterial septa and cell walls. Cefprozil is a second-generation cephalosporin antibacterial drug. There is a benzene ring at the C-3 position of its cephalosporin core.
Cefprozil hydrate is a semi-synthetic, second-generation cephalosporin marketed under the brand name Cefzil. It is a stabilized hydrate form of cefprozil. It is effective against a variety of bacterial infections and is known for its good oral bioavailability and clinical efficacy. It has received regulatory approval in many countries. |
| Molecular Formula |
C18H21N3O6S
|
|---|---|
| Molecular Weight |
407.4408
|
| Exact Mass |
407.115
|
| CAS # |
121123-17-9
|
| Related CAS # |
Cefprozil;92665-29-7
|
| PubChem CID |
6436628
|
| Appearance |
White to off-white solid powder
|
| Density |
1.534g/cm3
|
| Boiling Point |
803.1ºC at 760 mmHg
|
| Melting Point |
220ºC
|
| Flash Point |
439.5ºC
|
| LogP |
1.671
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
699
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C/C=C/C1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O.O
|
| InChi Key |
ALYUMNAHLSSTOU-CIRGZYLNSA-N
|
| InChi Code |
InChI=1S/C18H19N3O5S.H2O/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26)1H2/b3-2+/t12-,13-,17-/m1./s1
|
| Chemical Name |
(6R,7R)-7-[[(2R)-2-Amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(E)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic
acid hydrate
|
| Synonyms |
Cefzil Cefprozil hydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~1.1 mg/mL (~2.70 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4543 mL | 12.2717 mL | 24.5435 mL | |
| 5 mM | 0.4909 mL | 2.4543 mL | 4.9087 mL | |
| 10 mM | 0.2454 mL | 1.2272 mL | 2.4543 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA